SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Current opinion in the molecular genetics of Adams-Oliver syndrome

Southgate, L (2019) Current opinion in the molecular genetics of Adams-Oliver syndrome. Expert Opinion on Orphan Drugs, 7 (1). pp. 21-26. ISSN 2167-8707 https://doi.org/10.1080/21678707.2019.1559049
SGUL Authors: Southgate, Laura

[img] PDF Accepted Version
Restricted to Repository staff only until 27 December 2019.
Available under License ["licenses_description_publisher" not defined].

Download (514kB)

Abstract

Introduction: Adams–Oliver syndrome (AOS) is an orphan disorder of terminal transverse limb defects and aplasia cutis congenita, hypothesized to occur as a consequence of disordered vasculogenesis. AOS is estimated to affect 1 in 225,000 live births; however, comprehensive studies of geographical prevalence remain limited. Areas covered: This review summarizes current opinion in the molecular genetics of AOS and provides recommended updates to the diagnostic criteria. Understanding of the clinical features associated with AOS has been much improved due to recent advancement in establishing the underlying genetic causes of the condition. To date, six causal genes have been described, which together specifically implicate Rho GTPase dysregulation and perturbed Notch signaling as central to disease development. Despite these genetic advances, mutations in the established genes only represent 36% of reported AOS cases, indicating a large degree of missing heritability still to be resolved. Furthermore, the fundamental mechanisms underlying AOS remain undefined, impeding diagnostic and treatment progression. Expert opinion: Further work to examine structural variation and identify novel genes is necessary to explain the missing heritability in AOS. In the future, dedicated functional analyses will be required to delineate the pathogenic mechanisms and facilitate focused evaluation of targeted therapies.

Item Type: Article
Additional Information: This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Opinion on Orphan Drugs on 27/12/18, available online: http://www.tandfonline.com/10.1080/21678707.2019.1559049.
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Expert Opinion on Orphan Drugs
ISSN: 2167-8707
Dates:
DateEvent
2 January 2019Published
27 December 2018Published Online
11 December 2018Accepted
Publisher License: Publisher's own licence
Projects:
Project IDFunderFunder ID
204809/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
URI: http://openaccess.sgul.ac.uk/id/eprint/110568
Publisher's version: https://doi.org/10.1080/21678707.2019.1559049

Actions (login required)

Edit Item Edit Item